# Trial of BDC-1001 +/- Pertuzumab in Subjects With HER2-Positive Metastatic Breast Cancer

> **NCT05954143** · PHASE2 · TERMINATED · sponsor: **Bolt Biotherapeutics, Inc.** · enrollment: 11 (actual)

## Conditions studied

- Metastatic Breast Cancer
- HER2-positive Breast Cancer

## Interventions

- **DRUG:** BDC-1001
- **DRUG:** Pertuzumab

## Key facts

- **NCT ID:** NCT05954143
- **Lead sponsor:** Bolt Biotherapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2023-11-30
- **Primary completion:** 2024-09-20
- **Final completion:** 2024-09-25
- **Target enrollment:** 11 (ACTUAL)
- **Why stopped:** Sponsor Decision
- **Last updated:** 2025-11-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05954143

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05954143, "Trial of BDC-1001 +/- Pertuzumab in Subjects With HER2-Positive Metastatic Breast Cancer". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT05954143. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*